论文部分内容阅读
许多研究表明,二甲双胍治疗可以减缓糖耐量异常患者的血糖升高,从而减慢糖尿病的发生。这表明在糖尿病一经诊断即开始二甲双胍治疗可以减慢胰岛素分泌的丢失。因此,美国糖尿病协会(ADA)和欧洲糖尿病协会(EASD)指南中提出2型糖尿病(T2DM)一经诊断,就应在生活方式干预的同时首选二甲双胍治疗。虽然有临床试验表明,二甲双胍的失效率为每年4%,但在目前的临床实践中并无有关失效率的研究,故本研究评估单药使用二甲双胍后达到HbA_1c<7.0%患者的二甲双胍继发失效率,并探讨有无可预测治疗
Many studies have shown that metformin treatment can slow the blood sugar in patients with impaired glucose tolerance, thereby slowing the incidence of diabetes. This suggests that the onset of diabetes mellitus begins with metformin therapy and may slow the loss of insulin secretion. Therefore, guidelines for the American Diabetes Association (ADA) and European Diabetes Association (EASD) suggest that once diagnosed with type 2 diabetes mellitus (T2DM), metformin should be preferred at the same time as lifestyle interventions. Although clinical trials have shown that the failure rate of metformin is 4% per year, there is no study on the failure rate in current clinical practice. Therefore, this study evaluated the secondary failure of metformin in patients with HbA_1c <7.0% after monotherapy with metformin Rate and explore whether there is any predictable treatment